<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02084784</url>
  </required_header>
  <id_info>
    <org_study_id>2011CB707700</org_study_id>
    <secondary_id>973</secondary_id>
    <nct_id>NCT02084784</nct_id>
  </id_info>
  <brief_title>Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research</brief_title>
  <official_title>Study of Surgical Navigation System in Detection of Sentinel Lymph Node of Early Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Cancer Hospital of Shantou University Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yijishan Hospital of Wannan Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the sentinel lymph node (SLN) detection rate of early&#xD;
      breast cancer patients between using Indocyanine green (ICG) and Methylene blue with a novel&#xD;
      surgical navigation system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the sentinel lymph node (SLN) in patients with early stage breast cancer is&#xD;
      vital in selecting the appropriate surgical approach. However, the existing methods,&#xD;
      including methylene blue and nuclides, possess low efficiency and effectiveness in mapping&#xD;
      SLNs, and to a certain extent exert side effects during application. Indocyanine green (ICG),&#xD;
      as a fluorescent dye, has been proved reliable usage in SLN detection by several other&#xD;
      groups. In this paper, the investigators introduce a novel surgical navigation system to&#xD;
      detect SLN with ICG. This system contains two charge-coupled devices (CCD) to simultaneously&#xD;
      capture real-time color and fluorescent video images through two different bands. During&#xD;
      surgery, surgeons only need to follow the fluorescence display. In addition, the system saves&#xD;
      data automatically during surgery enabling surgeons to find the registration point easily&#xD;
      according to image recognition algorithms. The investigators aim to show that the usage of&#xD;
      our surgical navigation system with ICG to detect SLNs in breast cancer patients is&#xD;
      technically feasible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sentinel lymph node detection rate</measure>
    <time_frame>1 year</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 1 year</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Sentinel Lymph Node</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Indocyanine green &amp; methylene blue,</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine green</intervention_name>
    <description>Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%</description>
    <arm_group_label>Indocyanine green &amp; methylene blue,</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylene blue</intervention_name>
    <description>Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%</description>
    <arm_group_label>Indocyanine green &amp; methylene blue,</arm_group_label>
    <other_name>MB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: (Before the test, all the subjects required for meeting the entry&#xD;
        requirements before they join the group)&#xD;
&#xD;
          -  female patients;&#xD;
&#xD;
          -  The preoperative core needle biopsy or open surgical excision biopsy diagnosis as&#xD;
             breast cancer;&#xD;
&#xD;
          -  tumor diameter â‰¤ 3cm;&#xD;
&#xD;
          -  No clinical examination of suspicious axillary lymph node-positive;&#xD;
&#xD;
          -  diagnosed clinical conditions can be directly surgery as I, II breast cancer patients;&#xD;
&#xD;
          -  preoperative clinical or radiologic evidence without distant metastases (M0);&#xD;
&#xD;
          -  signed informed consent.&#xD;
&#xD;
        Exclusion criteria: (Before the test, the subjects under any one of items to meet the&#xD;
        requirements can not be enrolled)&#xD;
&#xD;
          -  Sentinel lymph node biopsy history had received surgery or axillary area;&#xD;
&#xD;
          -  multi-center breast cancer or multiple lesions;&#xD;
&#xD;
          -  clinical axillary lymph node metastasis have been found;&#xD;
&#xD;
          -  mammary area had received neoadjuvant chemotherapy or radiotherapy;&#xD;
&#xD;
          -  inflammatory breast cancer;&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  no personal freedom and independent civil capacity.&#xD;
&#xD;
        Exclusion criteria: (trials, subjects necessary to meet the requirements of any one item,&#xD;
        exit the clinical trial research.)&#xD;
&#xD;
          -  severe allergic reaction occurs;&#xD;
&#xD;
          -  persistent allergic reaction;&#xD;
&#xD;
          -  subjects were required to withdraw from a clinical trial;&#xD;
&#xD;
          -  researchers consider it not appropriate to continue to participate in the clinical&#xD;
             trial investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chongwei Chi, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Key Laboratory of Molecular Imaging, Chinese Academy of Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100190</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.mitk.net/</url>
    <description>A Website from Key Laboratory of Molecular Imaging, Chinese Academy of Sciences</description>
  </link>
  <results_reference>
    <citation>Chi C, Ye J, Ding H, He D, Huang W, Zhang GJ, Tian J. Use of indocyanine green for detecting the sentinel lymph node in breast cancer patients: from preclinical evaluation to clinical validation. PLoS One. 2013 Dec 16;8(12):e83927. doi: 10.1371/journal.pone.0083927. eCollection 2013.</citation>
    <PMID>24358319</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>March 8, 2014</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Chongwei Chi, Ph.D</investigator_full_name>
    <investigator_title>Key Laboratory of Molecular Imaging, Chinese Academy of Sciences</investigator_title>
  </responsible_party>
  <keyword>Near-infrared fluorescence</keyword>
  <keyword>Image guided surgery</keyword>
  <keyword>Breast cancer;</keyword>
  <keyword>Sentinel lymph node biopsy</keyword>
  <keyword>Indocyanine green</keyword>
  <keyword>Methylene blue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

